From: Modelling upper respiratory viral load dynamics of SARS-CoV-2
Study | Reference | No. of patients | Country | Healthcare setting | Recruitment period | Age, years Median (IQR) | Non-Caucasian ethnicity, n (%) | Male, n (%) | Remdesivir therapy, n (%) | WHO Severity score, Range | Mortality, n (%) | No. of samples, n | Method of sample collection | No. of samples used for modelling ⊗ | Units†|
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Kim JY et al., J Korean Med Sci, 2020 [34] | 2 | Korea | Hospital | January 2020 | 35 (10–50) | 2(100) | 1 (50) | 0 | 3–4 | 0 | 26 | Clinical | 13 | 3 |
2 | Lui G et al., J Infect, 2020 [35] | 11 | Hong Kong | Multicentre, Hospital | February 2020 | 58 (42–70) | NK | 7(64) | 0 | 3–6/7 | 0 | 73 | Research protocol | 34 | 3 |
3 | Scott S et al., Clin Infect Dis, 2020 [36] | 1 | USA | Community | January 2020 | 26 | NK | 1(100) | 0 | 2 | 0 | 12 | Research protocol | 6 | 1 |
4 | Kim SE, Int J Infect Dis, 2020 [37] | 3 | Korea | Tertiary Hospital | February–April 2020 | 30 (25–30) | NK | 2 (67) | 0 | 3 | 0 | 21 | Research protocol | 21 | 1 |
5 | Gautret P et al., Int J Antimicrob Agents, 2020 [38] | 19 | France | Tertiary Hospital | March 2020 | 49 (36.5–57) | NK | 9 (47) | 0 | 3–6/7 | 0 | 126 | Research protocol | 125 | 1 |
6 | Young B et al., JAMA, 2020 [39] | 18 | Singapore | Multicentre, Tertiary Hospital | January–February 2020 | 47 (31–73*) | 16 (89) | 9 (50) | 0 | 3–6/7 | 0 | 216 | Research protocol | 160 | 1 |
7 | The COVID–19 Investigation team, Nat Med, 2020 [40] | 12 | USA | Multicentre, Community and Hospital | January 2020 | 53 (21–68*) | NK | 8 (67) | 3 (25) | 2–5 | 0 | 121 | Clinical | 69 | 1 |
8 | Wölfel R et al., Nature, 2020 [41] | 9 | Germany | Hospital | January 2020 | 41 (33–49) | NK | 9 (100) | NK | 3–4 | 0 | 96 | Research protocol | 79 | 3 |
9 | Vetter P et al., mSphere, 2020 [42] | 5 | Switzerland | Hospital | February 2020 | 28 (24–55) | NK | 5 (100) | 0 | 2–4** | 0 | 39 | Research protocol | 37 | 3 |
10 | Lavezzo E et al., Nature, 2020 [43] | 37 | Italy | Community and Hospital | February–March 2020 | 65 (55–75) | NK | 22 (59) | NK | 2–10 | 3 (8) | 55 | Research protocol | 6 | 3 |
11 | Xu Y et al., Nat Med, 2020 [44] | 6 | China | Paediatric cohort, Tertiary Hospital | January–February 2020 | 6 (4–11) | NK | 3 (50) | 0 | 3 | 0 | 37 | Research protocol | 34 | 1 |
12 | Shrestha N et al., Clin Infect Dis, 2020 [45] | 230 | USA | Healthcare worker cohort, non–hospitalised | March–April 2020 | 36 (29–51) | 70 (30) | 59 (26) | 0 | 2 | 0 | 528 | Clinical | 46 | 2 |
13 | Fajnzylber J et al., Nat Commun, 2020 [4] | 64 | USA | Multicentre, Tertiary Hospital | NK | 56 (42–69) | 76(43) | 40 (63) | 16 (25) | 2–10 | 8 (13) | 93 | Research Protocol | 0 | 3 |
14 | Yilmaz A et al., J Infec Dis, 2020 [46] | 54 | Sweden | Tertiary Hospital | February–April 2020 | 50.5 (36-58) | NK | 31(57) | NK | 2–10 | 3 (5) | 349 | Research Protocol | 137 | 2 |
15 | Alsharrah et al., J Med Virol, 2020 [47] | 29 | Kuwait | Paediatric cohort, Tertiary Hospital | February–April 2020 | 8.8 (4.7–12.4) | NK | 16 (55) | 0 | 3 | 0 | 75 | Clinical | 9 | 1 |
16 | Tan A et al., Cell Reports, 2020 [7] | 12 | Singapore | Tertiary Hospital | NK | 52.5 (32–65) | 10 (83) | 6(50) | NK | 3–10 | 1 (8) | 82 | Research Protocol | 53 | 1 |
17 | Salvatore PP et al., Clin Infec Dis, 2020 [48] | 93 | USA | Community | March–May 2020 | 37 (21–53) | 24 (22) | 43 (46) | 0 | 2 | 0 | 223 | Research Protocol | 41 | 1 |
Total | - | 605 | - | - | - | 42 (28–56) | - | 271 (45) | - | 2-10 | 15 (2) | 2172 | - | 870 | - |